Ítem
Solo Metadatos

Pharmacologic management of neuropsychiatric lupus

Mostrar el registro sencillo de la publicación
dc.creatorKivity, Shayespa
dc.creatorBaker, Britainspa
dc.creatorArango, Maria-Teresaspa
dc.creatorChapman, Joabspa
dc.creatorShoenfeld, Yehudaspa
dc.date.accessioned2020-05-26T00:07:58Z
dc.date.available2020-05-26T00:07:58Z
dc.date.created2016spa
dc.description.abstractNeuropsychiatric lupus affects above 50% of patients with systemic lupus erythematosus and may span from mild symptoms to acute devastating life-threatening ones. Owing to the clinical variability, most pharmacological data rely on small, uncontrolled trials and case reports. The mainstay of therapy relies on immune-suppression by glucocorticoids, in adjunction with cyclophosphamide or anti-B-cell therapy, in moderate to severe cases. In selected scenarios (e.g., chorea) intravenous immunoglobulin or plasmapheresis may be effective. Anticoagulation is warranted if anti-phospholipid antibodies are present. In parallel there may be a need for symptomatic treatment such as anti-epileptic or anti-depressive treatments, etc. In the future, more studies addressed to assess pathogenesis and preferred treatments of specific manifestations are needed in order to personalize treatments. © 2015 Taylor and Francis.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1586/17512433.2016.1111137
dc.identifier.issn17512433
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/24044
dc.language.isoengspa
dc.publisherTaylor and Francis Ltdspa
dc.relation.citationEndPage108
dc.relation.citationIssueNo. 1
dc.relation.citationStartPage103
dc.relation.citationTitleExpert Review of Clinical Pharmacology
dc.relation.citationVolumeVol. 9
dc.relation.ispartofExpert Review of Clinical Pharmacology, ISSN:17512433, Vol.9, No.1 (2016); pp. 103-108spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84949103666&doi=10.1586%2f17512433.2016.1111137&partnerID=40&md5=53718f0f688fe3084e4333e6eb595465spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAntimalarial agentspa
dc.subject.keywordcentral nervous systemeng
dc.subject.keywordBelimumabspa
dc.subject.keywordBlood group b antibodyspa
dc.subject.keywordChloroquinespa
dc.subject.keywordCyclophosphamidespa
dc.subject.keywordGlucocorticoidspa
dc.subject.keywordHydroxychloroquinespa
dc.subject.keywordImmunoglobulinspa
dc.subject.keywordMethylprednisolonespa
dc.subject.keywordMethylprednisolone sodium succinatespa
dc.subject.keywordMycophenolate mofetilspa
dc.subject.keywordPrednisonespa
dc.subject.keywordRituximabspa
dc.subject.keywordAnticonvulsive agentspa
dc.subject.keywordAntidepressant agentspa
dc.subject.keywordCyclophosphamidespa
dc.subject.keywordGlucocorticoidspa
dc.subject.keywordImmunosuppressive agentspa
dc.subject.keywordAnticoagulationspa
dc.subject.keywordComputer assisted tomographyspa
dc.subject.keywordHumanspa
dc.subject.keywordImmunosuppressive treatmentspa
dc.subject.keywordLupus erythematosus nephritisspa
dc.subject.keywordLupus vulgarisspa
dc.subject.keywordNeuropsychiatric lupusspa
dc.subject.keywordNuclear magnetic resonance imagingspa
dc.subject.keywordNuclear magnetic resonance spectroscopyspa
dc.subject.keywordPalliative therapyspa
dc.subject.keywordPharmaceutical carespa
dc.subject.keywordPhase 3 clinical trial (topic)spa
dc.subject.keywordPlasmapheresisspa
dc.subject.keywordPositron emission tomographyspa
dc.subject.keywordRandomized controlled trial (topic)spa
dc.subject.keywordReviewspa
dc.subject.keywordSingle photon emission computer tomographyspa
dc.subject.keywordSystematic review (topic)spa
dc.subject.keywordSystemic lupus erythematosusspa
dc.subject.keywordAnimalspa
dc.subject.keywordB lymphocytespa
dc.subject.keywordComplicationspa
dc.subject.keywordImmunologyspa
dc.subject.keywordLupus vasculitiseng
dc.subject.keywordPathophysiologyspa
dc.subject.keywordProceduresspa
dc.subject.keywordAnimalsspa
dc.subject.keywordAnticonvulsantsspa
dc.subject.keywordAntidepressive agentsspa
dc.subject.keywordB-lymphocytesspa
dc.subject.keywordCyclophosphamidespa
dc.subject.keywordGlucocorticoidsspa
dc.subject.keywordHumansspa
dc.subject.keywordImmunosuppressive agentsspa
dc.subject.keywordLupus erythematosuseng
dc.subject.keywordLupus vasculitiseng
dc.subject.keywordPlasmapheresisspa
dc.subject.keywordAnti-ribosomal p antibodiesspa
dc.subject.keywordCyclophosphamidespa
dc.subject.keywordDepressionspa
dc.subject.keywordNeuropsychiatric lupusspa
dc.subject.keywordSystemic lupus erythematosusspa
dc.titlePharmacologic management of neuropsychiatric lupusspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos